GLP-1 Drugs: Balancing Weight Loss Benefits with Potential Bone and Joint Risks

The rise of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic, Wegovy) and liraglutide, has revolutionized the management of type 2 diabetes and obesity. However, as long-term data emerges, researchers are uncovering potential musculoskeletal side effects that warrant careful consideration. Even as these medications offer significant benefits in glycemic control and weight loss, a growing body of evidence suggests a possible link to increased risks of osteoporosis, gout, and osteomalacia.

The Emerging Musculoskeletal Concerns

A study presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) analyzed data from over 146,000 individuals and found a slightly elevated risk associated with GLP-1 RA use: a 0.9% increase in osteoporosis diagnoses, a 0.8% increase in gout cases, and a 0.1% increase in osteomalacia [1]. These findings highlight the need for a nuanced understanding of the long-term effects of these medications.

Why the Increased Risk?

Several factors may contribute to these observed risks. Rapid and substantial weight loss, a common outcome of GLP-1 RA therapy, can place stress on the skeletal system. Rapid fat loss can lead to a surge in uric acid levels, triggering gout attacks. Perhaps most concerning, these medications can suppress appetite, potentially leading to deficiencies in essential nutrients like calcium and vitamin D, which are crucial for bone health [1].

A Paradoxical Benefit: Improved Postoperative Outcomes

Interestingly, research also suggests a potential benefit of GLP-1 RA use in the context of orthopedic surgery. Studies indicate that patients taking GLP-1 RAs may experience improved recovery rates after procedures like hip or knee replacement. This is likely due to reduced mechanical loading on joints and better control of inflammation associated with osteoarthritis [1]. This dual effect – potential long-term risks alongside short-term benefits – underscores the complexity of these medications.

Anesthesia Considerations and GLP-1 RAs

Beyond bone health, GLP-1 RAs can also impact anesthesia during surgical procedures. These medications can delay gastric emptying, leading to gastroparesis (stomach paralysis) and increasing the risk of complications such as delayed emergence from anesthesia, aspiration, and aspiration pneumonitis [2]. A study presented at the 2025 AAOS Annual Meeting recommended discontinuing semaglutide two weeks before total joint arthroplasty (TKA) or total hip arthroplasty (THA) to mitigate these anesthesia-related risks [2].

The Path Forward: Personalized Prescriptions and Monitoring

The relative novelty of GLP-1 RAs means that our understanding of their systemic effects is still evolving. Researchers estimate that approximately 12% of Americans are currently taking a GLP-1 medication, with as many as 35% expressing interest [3]. It’s crucial to avoid demonizing these treatments, but rather to refine their use through personalized prescriptions and vigilant monitoring. Clinicians should closely monitor bone density, particularly in patients with pre-existing risk factors for osteoporosis.

“Any medication that sees such rapid adoption warrants close examination,” emphasizes Muaaz Wajahath, a medical student involved in the AAOS research [1]. A diet rich in essential nutrients and regular physical activity remain vital for protecting skeletal health during weight loss treatment.

Key Takeaways

• GLP-1 RAs are associated with a slightly increased risk of osteoporosis, gout, and osteomalacia.
• These medications may improve postoperative outcomes after certain orthopedic surgeries.
• Discontinuing semaglutide 14 days before total joint arthroplasty can reduce anesthesia-related risks.
• Personalized prescriptions and close monitoring are essential for maximizing benefits and minimizing risks.